Altimmune outlines 1,800-patient Phase III MASH trial and signals cash runway into 2028 as pemvidutide advances
Source: SeekingAlpha
2026-03-05 14:16:56 ET
More on Altimmune
- Altimmune, Inc. (ALT) Q4 2025 Earnings Call Transcript
- Altimmune Outlook: Where Pemvidutide Phase 3 Is Heading In 2026
- Altimmune: Why Breakthrough Status Isn't A 'Buy' Signal Just Yet
- Altimmune to start late-stage trial for MASH candidate this year
- Altimmune prices $75M direct offering
Read the full article on Seeking Alpha
For further details see:
Altimmune outlines 1,800-patient Phase III MASH trial and signals cash runway into 2028 as pemvidutide advances
Altimmune Inc.
NASDAQ: ALT
ALT Trading
4.18% G/L:
$3.985 Last:
1,609,658 Volume:
$3.90 Open:
ALT Latest News
March 05, 2026 07:00:00 am
Altimmune Announces Fourth Quarter and Full-year 2025 Financial Results and Business Updates
February 26, 2026 05:00:00 pm
Forget Altimmune: This Proven Obesity?Drug Giant Is the Better Weight?Loss Play
ALT Stock Data
$533,138,746
107,868,919
0.53%
58
N/A
Biotechnology & Life Sciences
Healthcare
US
Gaithersburg
